London, February 4, 2025 – Coulter Partners, the global expert in building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Our Future Health and is pleased to announce the placement of Andrew Miles, as Chief Business Officer (CBO).Our Future Health is an ambitious collaboration between the public, charity and private sectors to build the UK’s largest ever health research program – bringing people together to develop new ways to prevent, detect and treat disease such as dementia, cancer, diabetes…
We’re delighted to announce that Samuel Atack will be stepping into the role of Operations Director at Stevenage Bioscience Catalyst on 1st April 2025 when current Operations Director Dave Mudd retires.
After four years as Facilities & Estates Manager, Sam has been instrumental in delivering major facilities-led projects while supporting and developing the Operations team. His expertise includes Health & Safety, ESG, strategic oversight, and project management.
With a strong focus on operational excellence, sustainability, and stakeholder engagement, Sam is passionate about driving…
Minister Vallance underlines how Oxford-Cambridge corridor ambitions can boost whole UK
Science Minister Vallance today visited semiconductors and life sciences firms in Cambridgeshire, following his appointment as Oxford-Cambridge Innovation Champion
In new role, Vallance will convene local, national and business leaders to deliver coordinated action that drives investment, pulls in investment and unleashes growth
Vallance will build on national responsibilities as Science Minister to strengthen connections between OxCam and wider UK, so this region is an economic engine for the…
Calling all oncology startup founders! Fancy winning £50,000-worth of resources like lab space and tailored support? Last chance to apply for the fantastic Discovery Spark accelerator programme: 💡 Work with expert mentors to refine your strategy and storytelling🌐 Join a network of founders and industry leaders 🏆 Compete for resources like free lab space and tailored support worth over £50,000 Apply now: https://lnkd.in/ew_wSHgf
Search HighlightsRecent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech. This quarter’s successful placements include:Function, Focus area, LocationCEO, Antibody-based therapies, USCEO, Oncolytic viruses, UKCEO, Oncology biotech, SpainChief Financial Officer, Nanotechnology diagnostics, SwitzerlandChief Innovation Officer, Connected medical devices, FranceChief R&D Officer, Gene-encoded drug discovery, UKChief Commercial Officer, Computational chemistry, UKChief…
London, January 28, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for ICR Healthcare and is pleased to announce the placement of Sarah Elton-Farr as Partner, effective April 2025. ICR Healthcare is a leading global strategic communications and investor relations advisory firm specializing in the healthcare sector. Sarah Elton-Farr joins the firm's London office, complementing other recent senior-level appointments and promotions, and…
Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research.
This federated network leverages Lifebit’s cutting-edge Platform to ensure secure access to standardised datasets of millions of cancer patients from multiple international institutions for use in secure, large-scale cross-cohort analyses.
Under the partnership agreement, Cancer Research Horizons becomes a member of the network with the ability to upload information on its datasets to the Lifebit Platform. Once available on the platform…
AMSBIO has launched MatriMix for PDX, a fully defined extracellular matrix (ECM) hydrogel comprising of collagen, laminin-511 E8 fragments and hyaluronic acid optimized to support patient-derived xenograft (PDX) studies.
A PDX model uses a patient's tumor tissue to create a growing tumor in an immunodeficient mouse. They retain the histological and genetic characteristics of the patient’s original tumor, offering a superior platform for studying cancer biology and drug responses, allowing researchers to develop new treatments through drug screening and toxicology studies.…
Life sciences dealmaking volume is stable, but value is down. The 2025 edition of the EY Firepower report explores how life sciences companies can secure a more confident future with smarter, smaller deals.
Key takeaways from the EY 2025 Firepower analysis:
2024: A reset year? Deal value fell in 2024, as life sciences companies turned away from the major M&A plays of 2023 to focus on bolt-ons and other smaller strategic plays.
Deal or no deal? Drivers and restraints in 2025. The industry still faces significant growth gaps, has significant M&A Firepower and is expecting policy…
RSM UK’s co-leads of life sciences, Laragh Jeanroy and Graham Bond, highlight three key themes dominating the sector in 2025:
Tighter fundingThe value of private equity (PE) buyouts in the UK life sciences sector jumped from £778m in 2023 to £5.3bn in 2024, according to Pitchbook. However, the number of deals has remained fairly steady over the years, increasing from 10 in 2023 to 13 in 2024. A large proportion of PE and venture capital investment in the sector focused on traditional pharmaceuticals last year.
Laragh Jeanroy said: “High interest rates over the past year, and therefore, the…